PLX4720, a potent and selective RAF inhibitor, has demonstrated robust antitumor activity against RAF-mutant melanoma in vitro and in vivo.318 Vemurafenib (PLX4032), an analog of PLX4720, exhibits improved pharmacokinetic properties compared to PLX4720, and has received approval for the treatment of advanced melanomas and other cancers harboring RAF mutations.319,320 Vemurafenib has shown exceptional efficacy with manageable side effects, both as a monotherapy and when combined with MEK inhibitors, for patients with RAF mutant cancer. The gene discussed is MAP2K7; the disease is melanoma.